Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Sulopenem - Iterum Therapeutics

Drug Profile

Sulopenem - Iterum Therapeutics

Alternative Names: CP-70,429

Latest Information Update: 29 Nov 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Pfizer
  • Developer Iterum Therapeutics; Pfizer
  • Class Antibacterials; Aza compounds; Beta-lactams; Esters; Penems; Small molecules
  • Mechanism of Action Cell wall inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Intra-abdominal infections; Urinary tract infections
  • Discontinued Bacterial infections; Community-acquired pneumonia

Most Recent Events

  • 18 Nov 2019 Iterum Therapeutics completes enrolment in the phase III SURE 2 trial for Urinary tract infections (Complicated) in Estonia, Georgia, Hungary, Latvia and USA (NCT03357614)
  • 02 Oct 2019 Iterum Therapeutics completes a phase III trial in Intra-abdominal infections (complicated) in USA, Poland, Latvia, Hungary, Georgia, Estonia, Bulgaria (IV) (NCT03358576)
  • 14 Aug 2019 Iterum Therapeutics announces intention to submit NDA to US FDA for Intra-abdominal infections and Urinary tract infections in the first half of 2020
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top